TBPH

+ Watchlist + Portfolio

Theravance Biopharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $16.99
52-Week Range: $13.08 – $21.03
Market Cap: $880.02M
P/E (TTM): 16.30
EPS (TTM): 1.04
Dividend Yield: —

Advanced Metrics

Price/Book: 3.00
PEG Ratio: —
Return on Equity: 20.91%
Return on Assets: 1.33%
Gross Margin: 75.06%
Operating Margin: 8.89%
Profit Margin: 51.58%
Current Ratio: 13.54
Debt/Equity: 0.13
Total Debt: $38.57M
Free Cash Flow: $5.30M
Revenue Growth: -20.90%
Earnings Growth: —
Enterprise Value: $533.01M

TBPH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$51.35M	$57.42M	$64.38M	$107.46M
Research & Development	$63.39M	$40.62M	$37.64M	$37.41M
Selling, General & Admin	$67.07M	$70.09M	$69.17M	$73.65M
Operating Expenses	$130.47M	$110.72M	$106.82M	$111.07M
Operating Income	-$79.12M	-$53.29M	-$42.44M	-$3.60M
EBITDA	-$79.42M	-$42.66M	-$38.45M	$134.52M
Pretax Income	-$92.81M	-$49.27M	-$44.61M	$129.25M
Income Tax	$9.00K	$5.92M	$11.80M	$23.35M
Net Income	$872.13M	-$55.19M	-$56.42M	$105.89M
Diluted EPS	11.85	-1.00	-1.15	2.06
Diluted Shares	73.59M	55.30M	48.85M	51.51M

TBPH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$298.17M	$39.55M	$37.80M	$167.81M
Receivables	$16.79M	$17.47M	$68.44M	$95.54M
Current Assets	$353.46M	$133.54M	$161.07M	$418.46M
Total Assets	$607.40M	$382.00M	$354.16M	$485.57M
Current Liabilities	$28.71M	$24.77M	$32.09M	$38.30M
Total Debt	$52.16M	$49.16M	$49.82M	$42.70M
Total Liabilities	$165.60M	$169.00M	$178.62M	$188.85M
Retained Earnings	-$853.91M	-$909.10M	-$965.52M	-$859.63M
Shareholders' Equity	$441.80M	$213.00M	$175.54M	$296.72M
Working Capital	$324.75M	$108.77M	$128.98M	$380.16M

TBPH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$186.99M	-$27.00M	-$11.54M	$238.54M
Capital Expenditure	-$572.00K	-$2.49M	-$332.00K	-$42.00K
Free Cash Flow	-$187.56M	-$29.48M	-$11.87M	$238.50M
Depreciation & Amortisation	$7.02M	$4.26M	$3.62M	$2.81M
Stock-Based Compensation	$39.73M	$25.37M	$21.39M	$18.48M
Investing Cash Flow	$1.15B	-$32.70M	$12.28M	-$105.28M
Financing Cash Flow	-$758.81M	-$198.93M	-$2.50M	-$3.25M
Share Repurchases	-$132.28M	-$199.55M	-$3.10M	-$4.03M
Net Change in Cash	$208.21M	-$258.63M	-$1.75M	$130.01M

TBPH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$15.39M	$26.20M	$19.99M	$45.89M	$17.70M
Research & Development	$11.45M	$10.49M	$8.11M	$7.36M	$5.83M
Selling, General & Admin	$18.37M	$18.43M	$18.33M	$18.52M	$17.72M
Operating Expenses	$29.82M	$28.92M	$26.45M	$25.88M	$23.55M
Operating Income	-$14.43M	-$2.73M	-$6.46M	$20.01M	-$5.85M
EBITDA	-$12.44M	$74.80M	-$1.68M	$73.85M	-$5.63M
Pretax Income	-$14.14M	$73.21M	-$2.89M	$73.07M	-$6.47M
Income Tax	-$559.00K	$18.37M	-$6.50M	$12.04M	-$1.54M
Net Income	-$13.58M	$54.84M	$3.62M	$61.02M	-$4.93M
Diluted EPS	-0.27	1.08	0.07	1.15	-0.10
Diluted Shares	49.71M	50.73M	51.91M	53.05M	51.28M

TBPH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$110.61M	$281.93M	$174.77M	$167.81M	$288.10M
Receivables	$15.35M	$21.92M	$18.27M	$95.54M	$15.58M
Current Assets	$150.26M	$366.29M	$354.70M	$418.46M	$417.63M
Total Assets	$343.58M	$426.04M	$415.46M	$485.57M	$472.31M
Current Liabilities	$31.50M	$54.63M	$37.41M	$38.30M	$31.77M
Total Debt	$48.16M	$46.46M	$44.59M	$42.70M	$40.50M
Total Liabilities	$177.60M	$201.19M	$182.78M	$188.85M	$181.72M
Retained Earnings	-$979.10M	-$924.27M	-$920.65M	-$859.63M	-$864.56M
Shareholders' Equity	$165.98M	$224.85M	$232.68M	$296.72M	$290.59M
Working Capital	$118.76M	$311.66M	$317.29M	$380.16M	$385.86M

TBPH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$43.04M	$208.07M	-$6.51M	-$6.06M	$73.28M
Capital Expenditure	—	—	—	-$8.00K	—
Free Cash Flow	$43.04M	$208.04M	-$6.51M	-$6.07M	$73.28M
Depreciation & Amortisation	$1.05M	$927.00K	$636.00K	$196.00K	$835.00K
Stock-Based Compensation	$4.88M	$4.54M	$4.58M	$4.48M	$4.50M
Investing Cash Flow	$30.63M	-$36.26M	-$100.25M	$588.00K	$52.59M
Financing Cash Flow	-$854.00K	-$503.00K	-$400.00K	-$1.49M	-$5.58M
Share Repurchases	-$874.00K	-$503.00K	-$678.00K	-$1.98M	-$5.82M
Net Change in Cash	$72.82M	$171.31M	-$107.15M	-$6.97M	$120.30M

Market Snapshot

About

Theravance Biopharma, Inc. is a diversified biopharmaceutical company focused on the discovery, development and commercialization of organ-selective medicines. The company has a portfolio of respiratory and gastrointestinal-focused programs at various stages of development.